- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Shield Therapeutics - Notice of Results | 2 | RNS | ||
| 21.02. | Shield Therapeutics sinks as strong performance marred by data issues | 7 | Alliance News | ||
| 21.02. | Shield Therapeutics - Unaudited Full Year Trading Update | 3 | RNS | ||
| 11.01. | Shield Therapeutics - New CFO to support US traction | 275 | Edison Investment Research | Shield Therapeutics has appointed Santosh Shanbhag as chief financial officer (CFO) and member of the executive leadership team. Mr. Shanbhag was previously the CFO of Nasdaq-listed Akili, which he... ► Artikel lesen | |
| 09.01. | IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO | 2 | Alliance News | ||
| 09.01. | Shield Therapeutics - Appointment of new Chief Financial Officer | 1 | RNS | ||
| 08.12.23 | Shield Therapeutics - Delivering what the doctor ordered | 370 | Edison Investment Research | Shield Therapeutics' US commercialisation efforts continue to gather steam, with prescription volumes gearing up in Q323 (27,750 prescriptions, a 76% sequential growth over Q2 and higher than the combined... ► Artikel lesen | |
| 07.12.23 | Shield Therapeutics reports strong US progress | 2 | Sharecast | ||
| 07.12.23 | Shield Therapeutics - Q3 2023 U.S. Commercial Highlights | 1 | RNS | ||
| 27.11.23 | Shield Therapeutics - PDMR Transaction Notification | 3 | RNS | ||
| 15.11.23 | Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team | 320 | EQS Group (EN) | Hardman & Co Research
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team 15-Nov-2023 / 07:30 GMT/BST
The issuer is solely... ► Artikel lesen | |
| 29.09.23 | Shield Therapeutics - Ramped up and heading into a stronger H223 | 493 | Edison Investment Research | Shield Therapeutics' H123 results were largely as expected. Despite the minor operational adjustments with the commercialisation ramp-up, our long-term expectations remain unchanged. H123 revenue of... ► Artikel lesen | |
| 25.07.23 | Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering | 452 | Dow Jones News | DJ Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
Hardman & Co Research
Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
25-Jul-2023... ► Artikel lesen | |
| 17.05.23 | Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q'23 Accrufer prescriptions | 406 | Dow Jones News | DJ Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q'23 Accrufer prescriptions
Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q'23 Accrufer... ► Artikel lesen | |
| 09.05.23 | Premier Miton Group Plc - Form 8.3 - Shield Therapeutics plc | 303 | PR Newswire | Premier Miton Group Plc - Form 8.3 - Shield Therapeutics plc
PR Newswire
London, May 9
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON... ► Artikel lesen | |
| 09.05.23 | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc | 311 | PR Newswire | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc
PR Newswire
London, May 9
FORM 8.3
PUBLIC DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES... ► Artikel lesen | |
| 05.05.23 | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc | 367 | PR Newswire | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc
PR Newswire
London, May 5
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT... ► Artikel lesen | |
| 04.05.23 | Shield Therapeutics - FY23 a key year for business traction | 372 | Edison Investment Research | Shield Therapeutics reported its FY22 preliminary results and Q123 business update, the key emphasis of which was the growing traction of Accrufer in the US following the December 2022 co-commercialisation... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,325 | +0,32 % | Bayer vor Hauptversammlung: Das müssen Sie jetzt wissen | In zwei Wochen ist es soweit. Dann steigt die diesjährige Hauptversammlung der Bayer AG, allerdings nur virtuell und ohne physische Präsenz. Der DAX-Konzern will sich unter anderem grünes Licht für... ► Artikel lesen | |
| PFIZER | 24,370 | -0,08 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer vor Zahlen fürs erste Quartal auf "Neutral" mit einem Kursziel von 30 US-Dollar belassen. Der Pharmakonzern dürften die... ► Artikel lesen | |
| AURORA CANNABIS | 6,035 | -0,33 % | Kursexplosion bei den Cannabis-Aktien Aurora und Canopy Growth: Jetzt kaufen oder liegen lassen? | Am Donnerstag machten die Cannabis-Aktien von Aurora und Canopy Growth aus einem ganz bestimmten zweistellige Kurssprünge. Sind die Papiere für Anleger jetzt eine Überlegung wert? Mehr als 20 Prozent.... ► Artikel lesen | |
| SANOFI | 86,63 | +0,03 % | Minimale Kursveränderung bei Aktie von Sanofi SA (86,55 €) | Am Aktienmarkt ist das Wertpapier von Sanofi SA aktuell unauffällig. Zuletzt zahlten Investoren für das Wertpapier 86,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Sanofi... ► Artikel lesen | |
| CANOPY GROWTH | 7,490 | +0,40 % | Canopy Growth's Big Step Toward Entry Into US Cannabis Market As DEA Rescheduling Looms | ||
| ASTRAZENECA | 128,25 | -0,08 % | BARCLAYS stuft ASTRAZENECA auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Astrazeneca vor Quartalszahlen und dem Investorentag des Pharmakonzerns von 12500 auf 13000 Pence angehoben und... ► Artikel lesen | |
| INNOCAN PHARMA | 0,177 | -2,21 % | X-Leak: Jetzt der Mega-Meilenstein - Kurseskalation vorprogrammiert? | ||
| VIATRIS | 10,515 | -0,47 % | Viatris Announces Product Donations To Direct Relief of More Than 7 Million Doses of Medicine To Support Access to Medicine and Healthcare | Long-standing partnership with Direct Relief assists crisis areas around the worldSTEINHAUSEN, SWITZERLAND / ACCESSWIRE / April 19, 2024 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today... ► Artikel lesen | |
| TRANSCANNA | 0,017 | 0,00 % | TransCanna Holdings Inc. Announces Closing of Loan Upsize | Vancouver, British Columbia--(Newsfile Corp. - December 22, 2023) - TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) ("TransCanna" or the "Company") today announces that is has entered into a second... ► Artikel lesen | |
| BEVCANNA ENTERPRISES | 1,245 | -3,86 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 23.02.2024 | The following instruments on XETRA do have their first trading 23.02.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.02.2024
Aktien
1 CA28655A1066 Eli Lilly and Company... ► Artikel lesen | |
| KHIRON LIFE SCIENCES | 0,029 | 0,00 % | Khiron Life Sciences Corp.: Khiron Life Sciences Announces Closing of the Sale of Its European Business | Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 9,562 | -1,21 % | Adhoc: Spexis AG: Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera | Spexis AG / Key word(s): Miscellaneous
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of... ► Artikel lesen | |
| AMPIO | 0,181 | 0,00 % | Ampio Pharmaceuticals, Inc. - 15-12G, Securities registration termination | ||
| ALLARITY THERAPEUTICS | 1,400 | -9,09 % | Allarity Therapeutics, Inc.: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b) | Boston (April 17, 2024)-Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today... ► Artikel lesen | |
| ELIXINOL WELLNESS | 0,002 | 0,00 % | ELIXINOL WELLNESS LIMITED: Application for quotation of securities - EXL |
Das Unternehmen SHIELD THERAPEUTICS PLC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,014 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
